A phase II trial of marimastat in advanced pancreatic cancer.
Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral m...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2001
|
| _version_ | 1797092780029247488 |
|---|---|
| author | Evans, J Stark, A Johnson, C Daniel, F Carmichael, J Buckels, J Imrie, C Brown, P Neoptolemos, J |
| author_facet | Evans, J Stark, A Johnson, C Daniel, F Carmichael, J Buckels, J Imrie, C Brown, P Neoptolemos, J |
| author_sort | Evans, J |
| collection | OXFORD |
| description | Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. |
| first_indexed | 2024-03-07T03:50:54Z |
| format | Journal article |
| id | oxford-uuid:c1391965-7bb5-459b-85cc-73c6924ea813 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:50:54Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:c1391965-7bb5-459b-85cc-73c6924ea8132022-03-27T05:59:54ZA phase II trial of marimastat in advanced pancreatic cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c1391965-7bb5-459b-85cc-73c6924ea813EnglishSymplectic Elements at Oxford2001Evans, JStark, AJohnson, CDaniel, FCarmichael, JBuckels, JImrie, CBrown, PNeoptolemos, JPancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. |
| spellingShingle | Evans, J Stark, A Johnson, C Daniel, F Carmichael, J Buckels, J Imrie, C Brown, P Neoptolemos, J A phase II trial of marimastat in advanced pancreatic cancer. |
| title | A phase II trial of marimastat in advanced pancreatic cancer. |
| title_full | A phase II trial of marimastat in advanced pancreatic cancer. |
| title_fullStr | A phase II trial of marimastat in advanced pancreatic cancer. |
| title_full_unstemmed | A phase II trial of marimastat in advanced pancreatic cancer. |
| title_short | A phase II trial of marimastat in advanced pancreatic cancer. |
| title_sort | phase ii trial of marimastat in advanced pancreatic cancer |
| work_keys_str_mv | AT evansj aphaseiitrialofmarimastatinadvancedpancreaticcancer AT starka aphaseiitrialofmarimastatinadvancedpancreaticcancer AT johnsonc aphaseiitrialofmarimastatinadvancedpancreaticcancer AT danielf aphaseiitrialofmarimastatinadvancedpancreaticcancer AT carmichaelj aphaseiitrialofmarimastatinadvancedpancreaticcancer AT buckelsj aphaseiitrialofmarimastatinadvancedpancreaticcancer AT imriec aphaseiitrialofmarimastatinadvancedpancreaticcancer AT brownp aphaseiitrialofmarimastatinadvancedpancreaticcancer AT neoptolemosj aphaseiitrialofmarimastatinadvancedpancreaticcancer AT evansj phaseiitrialofmarimastatinadvancedpancreaticcancer AT starka phaseiitrialofmarimastatinadvancedpancreaticcancer AT johnsonc phaseiitrialofmarimastatinadvancedpancreaticcancer AT danielf phaseiitrialofmarimastatinadvancedpancreaticcancer AT carmichaelj phaseiitrialofmarimastatinadvancedpancreaticcancer AT buckelsj phaseiitrialofmarimastatinadvancedpancreaticcancer AT imriec phaseiitrialofmarimastatinadvancedpancreaticcancer AT brownp phaseiitrialofmarimastatinadvancedpancreaticcancer AT neoptolemosj phaseiitrialofmarimastatinadvancedpancreaticcancer |